Clinical Trial: Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07728721) titled 'Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis' on July 22.

Brief Summary: This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Study Start Date: Aug. 25

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: DRUG: HSK50042 dose 1

HSK50042 taken orally once daily in the morning for 26 weeks.

DRUG: HSK50042 dose 2

HSK50042 taken orally once daily in the morning for 26 weeks.

DRUG:...